Research chemicalResearch chemicalPsychedelicLysergamide

1cP-LSD

Also known as 1-cyclopropanoyl-LSD · 1-cyclopropionyl-LSD

Written by enwyReviewed 4 Aug 20262 sources0 comments

1cP-LSD (1-cyclopropanoyl-LSD) is a lysergamide prodrug of LSD in which a cyclopropanoyl group is attached to the indole nitrogen. It is thought to convert to LSD in the body and produces essentially LSD-like effects. It emerged as a legal-market alternative to LSD and 1P-LSD. Active doses are in the microgram range; human data are almost entirely anecdotal.

01 Overview

1cP-LSD is a semi-synthetic lysergamide widely regarded as a prodrug that is hydrolysed to LSD in vivo, giving effects that users describe as very close to LSD, sometimes with a marginally slower onset. It appeared on the research-chemical market as successor compounds to LSD and 1P-LSD were introduced to sidestep national bans.

It is active in micrograms and typically distributed on blotter, so dosing precision is limited and potency can vary between batches. As with LSD, the principal risks are psychological, with mild vasoconstriction; overwhelming experiences arise mainly from misjudged dose. Controlled human pharmacology does not exist.

02 Mechanism

Lysergamide agonist at serotonin 5-HT2A (and other serotonin) receptors, likely acting via conversion to LSD in vivo.

03 Dosing

Tier	Dose	Route	Notes
Threshold	20–50 mcg	Oral	Active in micrograms; blotter dosing is imprecise.
Common	75–150 mcg	Sublingual	Broadly comparable to LSD; onset may be slightly slower.
Strong	150–300 mcg	Oral	Intense, long experience; higher risk of overwhelming effects.

04 Effects

Effect	Magnitude	Evidence
LSD-like visual psychedeliaColour, pattern and perceptual changes closely resembling LSD.	strong	Anecdotal
Mood elevation and introspectionEmotional openness and reflective states.		Anecdotal
Slightly slower onsetSome users report a marginally delayed onset versus LSD, consistent with a prodrug.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Mild vasoconstriction and stimulationMild peripheral vasoconstriction and increased heart rate, as with LSD.	Mild	Common	Anecdotal
Anxiety and difficult experiencesOverwhelming or frightening states can occur, particularly at higher doses or with imprecise blotter dosing.	Moderate	Common	Anecdotal

06 Legal status

Germany

NpSG

Controlled under German new-psychoactive-substances legislation. · as of Jan 2026

United States

Schedule I

May be treated as an LSD analogue under the Federal Analogue Act. · as of Jan 2026

07 References

Brandt SD, et al. Return of the lysergamides — analytical characterization of 1cP-LSDDrug Testing and Analysis, 2020

1cP-LSD entryPsychonautWiki

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.